Recently, lymphocytopenia has been evaluated as an independent biomarker of mortality in hospitalized patients diagnosed with community-acquired pneumonia (CAP) \[[@CR1], [@CR2]\]. In these studies, patients recruited were affected by CAP due to different etiology, and no specific differences have been observed in viral and bacterial etiology distribution. On the other hand, in influenza virus infection, lymphocytopenia has been identified as a risk factor for bacterial superinfections \[[@CR3]\], determining a worse prognosis. We would like to evaluate the potential role of lymphocytopenia as a prognostic factor in patients with pneumonia caused by influenza virus.

For this purpose, we performed a retrospective, observational study on patients hospitalized in a hospital in Rome with pneumonia due to influenza virus. Between January and April 2019, we observed 38 patients with either CAP (29 patients) or hospital-acquired pneumonia (9 patients) due to influenza virus (defined by the presence of fever, symptoms and signs of pneumonia syndrome, new onset of pulmonary infiltrates on chest X-rays or CT scans, and influenza virus detection on respiratory specimens). Consistent with already published data \[[@CR4]\], the rate of nosocomial infections found was high and requires substantial improvement of early diagnosis and infection control strategies. Focusing on the lymphocyte count at the onset of infection, with the adoption of a previously reported cutoff value of 724 lymphocytes/μl \[[@CR2]\], 23 patients were considered as affected by lymphocytopenic influenza virus pneumonia (L-IP) and 15 by a non-lymphocytopenic influenza virus pneumonia (NL-IP). As shown in Table [1](#Tab1){ref-type="table"}, in comparison with NL-IP, patients with L-IP were more commonly affected by COPD (*p* = 0.046), they more frequently required admission to the intensive care unit (*p* = 0.002) and invasive mechanical ventilation (*p* = 0.031) and presented a higher SOFA score at the time of diagnosis (*p* = 0.004); they also experienced more frequently secondary bacterial and fungal pulmonary superinfections. As shown in Table [1](#Tab1){ref-type="table"}, secondary bacterial pathogens were often multiple resistant nosocomial organisms as carbapenem-resistant *Acinetobacter baumannnii* and *Corynebacterium striatum* and methicillin-resistant *Staphylococcus aureus*. Notably, fungal pathogens were represented not only by *Aspergillus fumigatus* but also by *Pneumocystis jiroveci*. If the former association is well known, to our knowledge, only one case report has been published on *P. jiroveci* superinfection in an immunocompetent host affected by influenza virus \[[@CR5]\]. Analyzing only the influenza CAP patients, the results were similar: SOFA score at the time of diagnosis was higher in patients with L-IP (*p* = 0.013) and they experienced more frequently respiratory failure requiring oxygen support (*p* \< 0.001) and IMV (*p* = 0.045) (Table [1](#Tab1){ref-type="table"}). Moreover, all the episodes of superinfection were experienced by lymphocytopenic patients. Table 1Baseline characteristics, severity, and microbiology of pulmonary superinfections and outcomesCharacteristicsTotal influenza pneumonia (38)Influenza CAP (29)\< 724 lymphocytes/μl (*n* = 23)\> 724 lymphocytes/μl (*n* = 15)*p* value\*\< 724 lymphocytes/μl (*n* = 20)\> 724 lymphocytes/μl (*n* = 9)*p* valueAge, years71 (57--80)76 (66--80)0.68170 (58--78)78 (66--80)0.681Male sex6 (26%)8 (53%)0.2914 (20%)4 (44%)0.188N/L ratio*14.8 (9.4--19.3)4.9 (1.6--8.6)\< 0.00115.5 (12.9--30.6)6.8 (3.3--7.8)\< 0.001*Current smoking17 (74%)6 (40%)0.098*15 (75%)3 (33%)0.034*Alcohol abuse1 (4%)0 (0%)0.4131 (5%)0 (0%)0.502Corticosteroid1 (4%)1 (7%)0.7541 (5%)1 (11%)0.754Influenza virus CAP20 (87%)9 (60%)0.368------Influenza virus HAP3 (13%)6 (40%)0.656------Comorbidity Cardiovascolar18 (78%)10 (67%)0.42816 (80%)5 (56%)0.188 Neurologic7 (30%)6 (40%)0.5436 (30%)4 (44%)0.470 Psychiatric2 (9%)0 (0%)0.2402 (10%)0 (0%)0.334 Gastroenteric4 (17%)6 (40%)0.1222 (10%)3 (33%)0.135 COPD*8 (35%)1 (7%)0.046*7 (35%)1 (11%)0.188 Autoimmune3 (13%)2 (13%)0.9793 (15%)1 (11%)0.776 Nephrologic6 (26%)6 (40%)0.3673 (15%)4 (44%)0.096 Neoplastic2 (9%)1 (7%)0.8202 (10%)1 (11%)0.936 Metabolic10 (43%)3 (20%)0.1369 (45%)2 (22%)0.245 Genetic1 (4%)2 (13%)0.3151 (5%)1 (11%)0.561 Pregnancy0 (0%)1 (7%)0.2090 (0%)1 (11%)0.138 Diabetes6 (26%)3 (20%)0.6665 (25%)2 (22%)0.864Charlson comorbidity index5 (2--7)4 (2--5)0.2095 (2--7)4 (2--5)0.209Influenza type A13 (57%)12 (80%)0.1368 (40%)6 (80%)0.050 A-H1N110 (43%)3 (20%)0.1353 (15%)3 (33%)0.276 B0 (0%)0 (0%)1.0000 (0%)0 (0%)1.000Severity ICU*12 (52%)0 (0%)0.002*5 (25%)0 (0%)0.105 SOFA score*3 (2--4)1 (1--2)0.0043 (2--4)1 (1--2)0.013* No oxygen support1 (4%)3 (20%)0.124*1 (5%)7 (78%)\< 0.001* NIV4 (17%)1 (7%)0.3394 (20%)1 (11%)0.559 IMV*8 (35%)0 (0%)0.0317 (35%)0 (0%)0.045* ECMO2 (9%)0 (0%)0.2402 (10%)0 (0%)0.334Pulmonary superinfection Total superinfection*7 (30%)0 (0%)0.021*6 (30%)0 (0%)0.069 *A. baumannii*, *P. jiroveci*1 (4%)0 (0%)0.4131 (5%)0 (0%)0.502 *A. baumannii*1 (4%)0 (0%)0.4131 (5%)0 (0%)0.502 *MRSA*, *S. maltophila*, *A. fumigatus*1 (4%)0 (0%)0.4131 (5%)0 (0%)0.502 *C. striatum*1 (4%)0 (0%)0.4131 (5%)0 (0%)0.502 *A. fumigatus*3 (13%)0 (0%)0.4132 (10%)0 (0%)0.334Outcome LOS, days20 (11--40)22 (11--45)0.63320 (11--39)12 (10--22)0.633 Mortality7 (30%)2 (13%)0.4116 (30%)1 (11%)0.277Data are presented as median (interquartile range (IQR) 25--75%) for continuous variables or as simple frequencies (*n*) and percentages for categorical variables*N/L ratio* neutrophils/lymphocytes ratio, *CAP* community-acquired pneumonia, *HAP* hospital-acquired pneumonia, *COPD* chronic obstructive pulmonary disease, *ICU* intensive care unit, *SOFA score* Sequential Organ Failure Assessment score, *NIV* non-invasive ventilation, *IMV* invasive mechanical ventilation, *ECMO* extracorporeal membrane oxygenation, *LOS* length of stay\*For comparisons between groups, Fisher's exact test was used for dichotomous variables, the χ^2^ test was used for non-ordered categorical variables and the Mann-Whitney test was used for continuous variables

In our experience, although we evaluated a small sample, a more severe course of a disease might be expected in episodes of L-IP. Under these circumstances, even otherwise immunocompetent patients seem to be at increased risk for opportunistic pulmonary superinfections. Based on the abovementioned, L-IP would require close clinical monitoring for these potentially fatal infectious complications possibly including anti-*Aspergillus* prophylaxis.
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